The Utility of Comprehensive Metabolic Panel Tests for the Prediction of Bronchopulmonary Dysplasia in Extremely Premature Infants.
Alkaline Phosphatase
/ blood
Biomarkers
/ blood
Birth Weight
Blood Chemical Analysis
Blood Proteins
/ analysis
Blood Urea Nitrogen
Bronchopulmonary Dysplasia
/ metabolism
Case-Control Studies
Cohort Studies
Female
Gestational Age
Humans
Infant, Extremely Premature
/ metabolism
Infant, Newborn
Magnesium
/ blood
Male
Regression Analysis
Reproducibility of Results
Retrospective Studies
Risk Factors
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
11
07
2019
accepted:
05
09
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
28
4
2020
Statut:
epublish
Résumé
Comprehensive metabolic panel tests (CMP) are routinely performed in extremely premature infants within the first days of life. The association between the parameters of first postnatal CMP and the risk of bronchopulmonary dysplasia (BPD) remains elusive. A retrospective analysis was performed to evaluate the correlation between the parameters of first postnatal CMP and the risk of BPD in a cohort of extremely premature infants (born with a gestational age less than 28 weeks or a birth weight less than 1000 grams) at the neonatal intensive care unit, Shenzhen Maternity and Child Healthcare Hospital, from January 2016 to October 2018. A multivariant regression model was built to assess the association of the first postnatal CMP with the development of BPD. A total of 256 extremely premature infants were included in this study. BPD developed in 76 (29.7%) infants. The first CMP in these infants was performed at 5 to 8 days after birth. The levels of blood urea nitrogen (BUN) and magnesium were significantly higher in infants with BPD compared to infants with no BPD (10.2 versus 7.5 mmol/L, Our findings indicate that a higher postnatal BUN level (>8.18 mmol/L) may be a predictor for the development of BPD in extremely premature infants.
Sections du résumé
BACKGROUND
BACKGROUND
Comprehensive metabolic panel tests (CMP) are routinely performed in extremely premature infants within the first days of life. The association between the parameters of first postnatal CMP and the risk of bronchopulmonary dysplasia (BPD) remains elusive.
METHODS
METHODS
A retrospective analysis was performed to evaluate the correlation between the parameters of first postnatal CMP and the risk of BPD in a cohort of extremely premature infants (born with a gestational age less than 28 weeks or a birth weight less than 1000 grams) at the neonatal intensive care unit, Shenzhen Maternity and Child Healthcare Hospital, from January 2016 to October 2018. A multivariant regression model was built to assess the association of the first postnatal CMP with the development of BPD.
RESULTS
RESULTS
A total of 256 extremely premature infants were included in this study. BPD developed in 76 (29.7%) infants. The first CMP in these infants was performed at 5 to 8 days after birth. The levels of blood urea nitrogen (BUN) and magnesium were significantly higher in infants with BPD compared to infants with no BPD (10.2 versus 7.5 mmol/L,
CONCLUSION
CONCLUSIONS
Our findings indicate that a higher postnatal BUN level (>8.18 mmol/L) may be a predictor for the development of BPD in extremely premature infants.
Identifiants
pubmed: 31772691
doi: 10.1155/2019/5681954
pmc: PMC6854975
doi:
Substances chimiques
Biomarkers
0
Blood Proteins
0
Alkaline Phosphatase
EC 3.1.3.1
Magnesium
I38ZP9992A
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5681954Informations de copyright
Copyright © 2019 Xueyu Chen et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Pediatrics. 2016 Jan;137(1):null
pubmed: 26672023
Arch Dis Child Fetal Neonatal Ed. 2015 Sep;100(5):F388-92
pubmed: 26199082
Am J Physiol Lung Cell Mol Physiol. 2018 Nov 1;315(5):L870-L881
pubmed: 30113229
Respir Res. 2018 May 10;19(1):93
pubmed: 29747649
Pediatr Res. 2019 Apr;85(5):693-696
pubmed: 30770862
Am J Respir Crit Care Med. 2015 Jul 15;192(2):134-56
pubmed: 26038806
Paediatr Respir Rev. 2017 Sep;24:17-18
pubmed: 28697967
J Perinatol. 2003 Sep;23(6):451-6
pubmed: 13679930
Rev Bras Ter Intensiva. 2018 Apr-Jun;30(2):174-180
pubmed: 29995082
Allergol Immunopathol (Madr). 2018 Jan - Feb;46(1):87-98
pubmed: 28668285
Respir Res. 2018 May 11;19(1):94
pubmed: 29751839
J Perinatol. 2015 Oct;35(10):813-7
pubmed: 26226242
Front Physiol. 2017 Jul 13;8:486
pubmed: 28751863
Respir Care. 2015 Jun;60(6):794-802; discussion 802-5
pubmed: 26070575
J Matern Fetal Neonatal Med. 2015;28(18):2197-200
pubmed: 25354286
J Pediatr. 2018 Jun;197:300-308
pubmed: 29551318
Clin Perinatol. 2015 Dec;42(4):797-806
pubmed: 26593079
J Perinatol. 2016 Dec;36(12):1045-1048
pubmed: 27583395
Biochem Pharmacol. 2016 Dec 1;121:18-32
pubmed: 27659811
Pediatrics. 2005 Dec;116(6):1353-60
pubmed: 16322158
PLoS One. 2018 Sep 24;13(9):e0204498
pubmed: 30248159
Cochrane Database Syst Rev. 2014;(12):CD000503
pubmed: 25473815
J Perinatol. 2016 Oct;36(10):878-82
pubmed: 27467562
Am J Respir Cell Mol Biol. 2019 Jun;60(6):667-677
pubmed: 30571144
Early Hum Dev. 2019 Apr;131:29-35
pubmed: 30825742
Diabetes Care. 2018 Jul;41(7):1339-1342
pubmed: 29559508
Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1101-L1153
pubmed: 28971976
JAMA Pediatr. 2015 Feb;169(2):e143676
pubmed: 25642906
Int J Mol Med. 2017 Jun;39(6):1403-1408
pubmed: 28440468
Front Immunol. 2018 Jan 05;8:1923
pubmed: 29354129